Allopurinol augmentation in the outpatient treatment of bipolar mania: A pilot study

Bipolar Disorders

Volumn 14, Issue 2, 2012, Pages 206-210

  Fan, Alexander ^a   Berg, Andrew ^a   Bresee, Catherine ^a   Glassman, Lisa Hayley ^a   Rapaport, Mark Hyman ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adenosine; Allopurinol; Augmentation; Bipolar; Caffeine; Mania

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; YOUNG MANIA RATING SCALE;

ADULT; ALLOPURINOL; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84858330202     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01001.x     Document Type: Article

References (19)

1. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
2. Gajwani P. Treatment-refractory bipolar disorder: classification to aid in clinical management. Expert Opin Pharmacother 2009; 10: 1907-1915.
3. Nayak GH, Prentice HM, Milton SL. Neuroprotective signaling pathways are modulated by adenosine in the anoxia tolerant turtle. J Cereb Blood Flow Metab 2011; 31: 467-475.
4. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; 193: 535-587.
5. Fuxe K, Marcellino D, Borroto-Escuela DO et al. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010; 16: 18-42.
6. Porkka-Heiskanen T, Kalinchuk AV. Adenosine, energy metabolism and sleep homeostasis. Sleep Med Rev 2011; 15: 123-135.
7. Shah U, Hodgson R. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. Curr Opin Drug Discov Devel 2010; 13: 466-480.
8. Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 2006; 1074: 444-450.
9. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991; 88: 7238-7241.
10. Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 253-259.
11. Togha M, Akhondzadeh S, Motamedi M, Ahmadi B, Razeghi S. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch Med Res 2007; 38: 313-316.
12. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485-489.
13. Machado-Vieira R, Soares JC, Lara DR et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008; 69: 1237-1245.
14. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20): 22-33.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
17. Sheehan DV. The Anxiety Disease. New York: Scribner's, 1983.
18. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326.
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences, (2nd ed.). Hillsdale: Lawrence Earlbaum Associates, 1988.